DUBLIN--(BUSINESS WIRE)--The "Musculoskeletal Drugs Market Global Briefing 2018" report has been added to ResearchAndMarkets.com's offering.
This report covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for this market.
Some of the major drugs in the market include Piroxicam Glaxo, Dolonex, Felden, and Piroxicam Pfizer.
Topical NSAIDs are being used for treatment of acute musculoskeletal pain in adults. In June 2015, medical research organization Cochrane published the results of its clinical trials to compare topical NSAIDs with placebo or other medicines in patients above 16 years with musculoskeletal pain. These results indicate that gel formulations of NSAIDs diclofenac and ketoprofen were more effective in treatment of strain, sprain, or muscle pull, as compared to placebo.
North America was the largest region in the musculoskeletal disorders drugs market in 2017, accounting for around 32% market share. This can be attributed to the high per capita healthcare expenditure and the development of cost effective drugs for musculoskeletal disorders. Western Europe was the second largest region accounting for around 22.5% market share. Asia Pacific was the third largest region accounting for around 22% market share.
Scope
- Markets Covered: Drugs For Rheumatoid Arthritis, Muscle Relaxants, and others.
- Time Series: Five years historic and forecast.
- Data: Market value in $ billions.
- Data Segmentations: Regional breakdowns, market share of competitors, key sub segments.
Companies Mentioned
- F. Hoffmann-La Roche Ltd.
- GlaxosmithKline Plc.
- Pfizer Inc.
- Daiichi Sankyo Company
- Limited
- Abbott Laboratories Inc.
- Johnson & Johnson
- Sanofi S.A.
- Novartis AG
- Otsuka Pharmaceutical Co. Ltd.
- Celgene Corporation
For more information about this report visit https://www.researchandmarkets.com/research/pmvjtm/global?w=4
